| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDM008 |
| P698 | PubMed publication ID | 17293601 |
| P50 | author | Fabrice André | Q41743842 |
| Ana Maria Gonzalez-Angulo | Q107718318 | ||
| Aman U Buzdar | Q114440916 | ||
| P2093 | author name string | K Anderson | |
| K R Hess | |||
| G N Hortobagyi | |||
| L Pusztai | |||
| W F Symmans | |||
| C Mazouni | |||
| T A Buchholz | |||
| D Frye | |||
| H M Kuerer | |||
| S-W Kau | |||
| P433 | issue | 5 | |
| P921 | main subject | preoperative chemotherapy | Q108532530 |
| paclitaxel | Q423762 | ||
| P304 | page(s) | 874-880 | |
| P577 | publication date | 2007-02-10 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers | |
| P478 | volume | 18 |
| Q36458727 | Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer |
| Q42850220 | Complete Pathological Remission in a Patient with Hormone-Receptor Positive and c-erbB-2 Expression-Negative Breast Cancer Treated with FAC Chemotherapy during Pregnancy |
| Q36678725 | Evaluation of biological pathways involved in chemotherapy response in breast cancer |
| Q36551617 | Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? |
| Q53674063 | Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. |
| Q39962699 | Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response |
| Q37287552 | Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries |
| Q35155460 | Management options in triple-negative breast cancer |
| Q33698446 | Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment |
| Q37609483 | Outcome after neoadjuvant chemotherapy in Asian breast cancer patients |
| Q36024666 | Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series |
| Q36972046 | Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer |
| Q86933946 | Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy |
| Q36977587 | Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. |
| Q92807885 | Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy |
| Q34048154 | The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells |
| Q33769821 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease |
| Q33900930 | Triple-negative breast cancer: role of specific chemotherapy agents |
Search more.